Aflibercept high-dose (8mg) related intraocular inflammation (IOI) - a case series.

Détails

ID Serval
serval:BIB_8FE22615F6E8
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Etude de cas (case report): rapporte une observation et la commente brièvement.
Collection
Publications
Institution
Titre
Aflibercept high-dose (8mg) related intraocular inflammation (IOI) - a case series.
Périodique
BMC ophthalmology
Auteur⸱e⸱s
Hoffmann L., Michels S., Eandi C., Karam M.A., Figueiredo ECO, Hatz K.
ISSN
1471-2415 (Electronic)
ISSN-L
1471-2415
Statut éditorial
Publié
Date de publication
02/12/2024
Peer-reviewed
Oui
Volume
24
Numéro
1
Pages
520
Langue
anglais
Notes
Publication types: Journal Article ; Case Reports
Publication Status: epublish
Résumé
Monitoring for potential inflammatory events following intravitreal anti-vascular endothelial factor (VEGF) injection is crucial with the use of new agents such as aflibercept 8 mg. Despite a safety profile comparable to aflibercept 2 mg in pivotal and phase 3 studies, reporting such cases in clinical practice helps evaluate potential risk of these agents.
In this case series, a cluster of 8 patients manifesting acute intraocular inflammation (IOI) after intravitreal aflibercept 8 mg injection at three different centers are described. All patients developed inflammation of the vitreous and anterior chamber within 2-17 days following the injection. All subjects had previously received intravitreal anti-vascular endothelial growth factor (VEGF) therapy (ranibizumab, aflibercept 2 mg or faricimab) without injection-related complications. No signs of vasculitis, papillitis or retinitis were noted. In view of the clinical presentation, vitreous cultures were not performed. Inflammation resolved with topical steroids and non-steroidal anti-inflammatory drugs over a course of 11-24 days with excellent visual recovery.
We report a cluster of injection-related ocular inflammation following intravitreal aflibercept 8 mg with at present unknown cause. It underlines the need for clinical awareness to detect such cases despite the low-risk safety profile in pivotal studies.
Mots-clé
Humans, Receptors, Vascular Endothelial Growth Factor/administration & dosage, Recombinant Fusion Proteins/administration & dosage, Recombinant Fusion Proteins/adverse effects, Intravitreal Injections, Female, Male, Aged, Angiogenesis Inhibitors/adverse effects, Angiogenesis Inhibitors/administration & dosage, Middle Aged, Aged, 80 and over, Endophthalmitis/diagnosis, Endophthalmitis/drug therapy, Endophthalmitis/chemically induced, Vascular Endothelial Growth Factor A/antagonists & inhibitors, Uveitis/drug therapy, Uveitis/diagnosis, Uveitis/chemically induced, Adverse event, Aflibercept 8 mg, Anti-VEGF, High dose, Intraocular inflammation
Pubmed
Open Access
Oui
Création de la notice
09/12/2024 15:10
Dernière modification de la notice
10/12/2024 7:12
Données d'usage